As part of its domestic growth strategy, Bristol Myers Squibb has announced plans to build a $2.3 billion 600,000-square-foot manufacturing campus in Houston, Texas where it will produce several types of medicines and leave room for future expansion with the growth of digital integration and automation technologies.
The biopharmaceutical company will produce small molecules, biologics, and antibody drug conjugates for a range of diseases at the campus, which boasts a modular and multimodal design, giving it the flexibility to adapt and reconfigure to meet shifting demand. The project is part of the company’s greater plan to invest $40 billion in the U.S. through 2030. As technology, automation, and digital integration advance, so too will the campus.
“We’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs,” Chairman and CEO Christopher Boerner said in a statement. “Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.” The Houston campus will expand Bristol Myers Squibb’s operational footprint incorporating “speed, quality and resilience into every stage of how medicines are made and delivered to patients,” the company said.
Texas was selected for its strength as a life sciences hub, home to a qualified and available workforce as well as government incentives and proximity to utilities and transportation infrastructure. The project received $4.89 million through the Texas Enterprise Fund and qualifies for incentives under the Texas Jobs, Energy, Technology and Innovation program as it is expected to create 500 new jobs. Construction is slated to run from 2027 to 2030.
